Krebs

Researchers reported at Digestive Disease Week (DDW) 2026 that older mice given fecal microbiota transplants made from their own preserved, younger-age stool samples showed less liver inflammation and injury—and none developed liver cancer in the experiment.

30. April 2026 Von KI berichtet Fakten geprüft

Researchers from the University of Geneva and Lausanne University Hospital report they have visualized, in three dimensions and under near-native conditions, how cytotoxic T cells organize their killing machinery at the immune synapse. The work, published in Cell Reports, applies cryo-expansion microscopy to human T cells and to tumor tissue samples, providing nanoscale views intended to support immunology and cancer research.

Die Spezialklinik Tekur Anbesa in Addis Abeba hat ein modernes Krebsbehandlungszentrum mit 27 Betten eröffnet, dessen Bau 6 Millionen Birr kostete. Die Einrichtung soll nach Angaben der Verantwortlichen die Qualität der Krebs- und Palliativversorgung verbessern. Pläne für den baldigen Ausbau weiterer ähnlicher Zentren wurden ebenfalls angekündigt.

15. April 2026 Von KI berichtet

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Scientists at McMaster University and the Hospital for Sick Children in Canada have discovered that oligodendrocytes, cells typically supporting nerve function, aid the growth of glioblastoma by sending signals to tumor cells. Blocking this communication slowed tumor progression in lab models. The findings suggest an existing HIV drug, Maraviroc, could be repurposed for treatment.

5. April 2026 Von KI berichtet Fakten geprüft

Researchers in Brazil report that an artificial-saliva formulation made with a lab-modified sugarcane protein, CaneCPI-5 (also written CANECPI-5), can bind to tooth enamel and help reduce bacterial activity and mineral loss in laboratory experiments designed to model the severe dental risks faced by head and neck cancer patients after radiotherapy. The work, published in the Journal of Dentistry, found the formulation performed best when combined with fluoride and xylitol.